Neuralstem Announces Adjustment to Inducement Grant Under Nasdaq Listing Rule 5636(c)(4)

Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients

Neuralstem Reports Second Quarter 2019 Fiscal Results

Neuralstem Announces Nasdaq Hearings Panel Grants Request For Continued Listing

Neuralstem Closes $7.5 Million Underwritten Public Offering

Neuralstem Announces Pricing of $7.5 Million Underwritten Public Offering

Neuralstem Appoints Mary Ann Gray, Ph.D., to Board of Directors

Neuralstem Announces a 1-for-20 Reverse Stock Split

Neuralstem Announces Publication of Results from Phase 1 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients

Neuralstem Announces Issuance of New Patent Covering Broad Therapeutic Use of Neural Stem Cells